About COURAGE THERAPEUTICS INC
Courage Therapeutics is a neuroendocrine company focused on developing precision therapeutics for genetic obesities, particularly targeting melanocortin-4 receptor haploinsufficiency (MC4R HI) with its lead candidate, CTX-B. The company is led by Dr. Roger Cone, a pioneer in melanocortin receptor biology.
Development of precision therapeutics for genetic obesitiesPreclinical and clinical research in MC4R pathway-driven obesityDrug discovery and development of MC4R agonistsTranslation of decades of research into therapeutic candidates
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to COURAGE THERAPEUTICS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.